In this study, 102 patients will be evenly randomized into two groups: one set to receive omega-3 fatty acids and the other a placebo. The process will be blinded, ensuring that neither the researchers nor the participants will know which group they are in. Each participant will take two capsules daily for a duration of 90 days, with the active group receiving capsules containing 1000 mg of fish oil each. All participants will be instructed to maintain their usual diet, lifestyle, and medication regimen. At the beginning and end of the study, various health assessments, including lipid panels and C-reactive protein measurements, will be conducted. Additionally, DNA samples will be collected for genotyping to identify patients with specific PPARG gene polymorphisms, leading to the creation of four distinct subgroups: those receiving omega-3 with and without polymorphisms, and those receiving placebo with and without polymorphisms.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
102
The active treatment, supplied by Soloways, LLC., contained omega-3 fatty acids (1000 mg of fish oil, of which 600 mg were eicosapentaenoic acid and 300 mg docosahexaenoic acid) per capsule. The subjects will take 2 capsules daily.
placebo capsules identical in appearance, matched for color coating, shape, and size with omega-3 fatty acids capsule
Center of New Medical Technologies
Novosibirsk, Novosibisk Region, Russia
the percent change in LDL-C for omega-3 fatty acids among patients with PPARG polymorphism
the percent change in LDL-C for omega-3 fatty acids compared with placebo among patients with PPARG polymorphism
Time frame: 90 days
the percent change in hsCRP
the percent change in hsCRP for omega-3 fatty acids compared with placebo among patients with PPARG polymorphism
Time frame: 90 days
the percent change in High-density lipoprotein cholesterol
the percent change in High-density lipoprotein cholesterol for omega-3 fatty acids compared with placebo among patients with PPARG polymorphism
Time frame: 90 days
the percent change in total cholesterol the percent change in total cholesterol
the percent change in total cholesterol for omega-3 fatty acids compared with placebo among patients with PPARG polymorphism
Time frame: 90 days
the percent change in serum triglycerides
the percent change in serum triglycerides for omega-3 fatty acids compared with placebo among patients with PPARG polymorphism
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.